Comparison of Khandu chakka leaves powder with Diclofenac Sodium tablet in the management of Pain

Comparative Efficacy Study of Ehretia Laevis Roxb. leaves Powder With Standard In Management Of Pain in the management of Pain - Comparative Efficacy Study of Ehretia Laevis Roxb. leaves Powder With Standard In Management Of Pain

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/032597

Enrollment

142

Registered

2021-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G892- Chronic pain, not elsewhere classified

Interventions

Intervention1: Ethretia laevis Roxb leaves powder: 500 mg powder three times a day Control Intervention1: Diclofenac Sodium Tablet: 50 mg two times a day

Eligibility

Inclusion criteria

Inclusion criteria: Musculo-Skeletal pain, Joint Pain, Back Pain and Cervical Pain

Exclusion criteria

Exclusion criteria: Abdominal Pain, Traumatic Pain, Pain due to life threatening conditions. Intolerable pain, Patients having abnormal haematological and biochemistry parameters.

Design outcomes

Primary

Measure	Time frame
management of painTimepoint: Pain assessment after every 3rd day	—

Secondary

Measure	Time frame
improvement in the painTimepoint: 15th day	—

Countries

India

Contacts

Public ContactRushikesh Thakre

Mahatma Gandhi Ayurved College Hospital And Research Centre

dr.rushu@gmail.com9765404039

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026